Here are six highlights from the company’s report:
1. The company raised EUR 37 million of new funds for a strong financial underpinning to execute its clinical and commercial strategy as well as bringing on a mix of high quality new investors onto the share register.
2. The headquarters moved to Gosselies Biopark in Belgium, securing commercial cell therapy producing capacity.
3. There was a new subsidiary established in the United States in the Boston biotechnology cluster in operation for United States clinical trials.
4. The first patient cohort of the Phase I/IIA novel allogeneic cell therapy product ALLOB demonstrated efficiency to treat delayed-union fracture of long bones.
5. Bone Therapeutics aims to further accelerate PREOB development, currently in the last phase clinical trail or treating osteonecrosis and non-union fractures.
6. Clinical trials for ALLOB will continue, and there is expected results from the first eight patients in the spinal fusion trial with ALLOB.
More articles on orthopedic devices:
LDR gets “Outperform” rating—5 key notes
Spinal Kinetics M6 disc replacement: Grood results 2 years postop
Allegheny Health Network incorporates MAKOplasty
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
